GlycoMimetics (FRA:GKO) Short Percentage of Float

View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of GlycoMimetics's Short Percentage of Float

For the Biotechnology subindustry, GlycoMimetics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlycoMimetics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's Short Percentage of Float falls into.

GlycoMimetics (FRA:GKO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (FRA:GKO) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

GLYC:USA

Address

9708 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.glycomimetics.com

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.